Sykehuset Innlandet HF — Clinical Trial Site

25 Registered trials

19 Currently recruiting

Organisation

Sykehuset Innlandet HF

Location

Brumunddal, Norway

Identifier

ORG-100030136

Address

P. O. Box 104, 2381, Norway

Departments

Department of Internal Medicine
Department of Medicine
Department of Neurology
Department of Oncologi
Department of Oncology
Department of Oncology and Center for Palliative Care Division Gjøvik
Department of Oncology and Radiotherapy
Department of Oncology and Radiotherapy and Center for Palliative Care
Dept. of Oncology
Div Psykisk helsevern - Hamar
Elverum
Gastroenterology
Hamar, Department of plastic- and reconstructive surgery
Medisinsk avdeling
Medisinsk avdeling, Lillehammer
N/A
Neurology
Oncology
Øre-nese-hals avdeling
Tynset, Department of Plastic and Reconstructive Surgery

Clinical trials at this site (25)

Search interface

Ketamine maintenance treatment for depression: A multicenter open-label randomized controlled trial (PreKET) Pending

2025-521330-29-00 Major Depression Disorder (MDD) 4
TENECTEPLASE IN CENTRAL RETINAL ARTERY OCCLUSION STUDY (TenCRAOS): A Prospective, randomised-controlled, double-dummy, double-blind phase 3 … Recruiting

2024-517606-29-00 Central retinal artery occlusion 5 2020-10-30
A Phase 2, Randomized, Double-Blind, Double-Dummy Study Evaluating the Efficacy, Safety and Biomarkers Effect of ILB® versus Riluzole in par… Recruiting

2024-513927-18-00 Amyotrophic Lateral Sclerosis 4 2026-02-16
Phase 3 Study of I-DXd Versus Docetaxel in mCRPC Recruiting

2024-517423-40-00 Metastatic Castration-Resistant Prostate Cancer 5 2025-06-23
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Smal… Recruiting

2024-512302-25-00 Resected or Unresectable KRAS G12C-mutant Non-Small Cel 5 2025-06-06
The Nordic Chronic Migraine Trial of CGRP monoclonal antibody and onabotulinumtoxin A dual therapy – a randomized-controlled double-blind tr… Recruiting

2024-517981-40-00 Chronic Migraine 5 2025-06-06
Precision cancer medicine in hard-to-treat rare cancers - repurposing drugs in earlier lines of treatment - MATRIX-RARE. Recruiting

2024-513779-42-02 Cancer 4 2025-03-27
Clinical trial comparing MK-2870 given with pembrolizumab to pembrolizumab alone in participants who have had surgery for NSCLC Recruiting

2023-508012-35-00 Newly diagnosed NSCLC with resectable clinical Stage II 5 2024-10-02
The Effect of Topical Tranexamic Acid on Postoperative Complications in Soft Tissue Plastic Surgery. A Multicenter Randomized Controlled Tri… Recruiting

2023-510381-28-01 Patients undergoing plastic surgical procedures with wo 6 2024-09-18
A Phase 2b Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects with Moderately to Severely Active Crohn’s Disease Recruiting

2023-506704-14-00 Moderately to Severely Active Crohn's Disease 4 2024-09-04
A study to discover if ZED1227 can improve continued celiac disease symptoms despite a gluten-free diet Recruiting

2023-506150-21-00 Celiac Disease 4 2024-05-29
COMBINATORY IMMUNOTHERAPY-2 (COM-IT-2) A phase 2 randomised open two-arm study to assess the tolerability and efficacy of immunotherapy comb… Recruiting

2023-510089-28-00 Non-small cell lung cancer (Stage IV) 9 2024-05-22
A Global Pivotal Placebo-Controlled Study of LY3537982 in Combination with Pembrolizumab and LY3537982 in Combination with Pembrolizumab, Pe… Recruiting

2023-503412-33-00 Stage IIIB-IIIC or Stage IV KRAS G12C-mutant non-small 5 2024-03-29
The CORTAD study Recruiting

2024-512888-31-00 Primary adrenal insufficiency (PAI) 11 2023-08-03
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Patients With Stage III Unresectabl… Recruiting

2023-506891-28-00 The target population of interest in this study is part 5 2022-05-02
Efficacy of Hyperbaric oxygen in addition to standard treatment for acute sudden deafness Recruiting

2024-510798-84-00 Idiopathic sudden sensorineural hearing loss (ISSNHL) 10 2022-01-28
Improving public cancer care by implementing precision medicine in Norway Recruiting

2023-507894-16-00 Cancer 4 2021-04-01
A research study to investigate the effects of CagriSema compared to placebo in people with type 2 diabetes and painful diabetic peripheral … Ended

2023-509662-38-00 Type 2 diabetes and painful diabetic peripheral neuropa 4 2025-01-22
A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascu… Ended

2022-502781-24-01 ASCVD - Atherosclerotic Cardiovascular Disease 5 2024-06-05
Phase II multicenter clinical trial: Mosunetuzumab for early relapse of follicular lymphoma in the Nordic countries (MERLIN/NLG-FL6/ML43841) Ended

2022-500100-21-01 Follicular lymphoma 4 2023-09-11
Is there a survival benefit of administering thoracic radiotherapy concurrently with immunnotherapy and chemotherapy for patients with exten… Ended

2023-505514-15-00 Small-cell lung cancer, extensive stage 5 2022-01-11
Phase 3 Randomized Study of Talazoparib with Enzalutamide in Men with DDR Gene Mutated mCSPC Ended

2024-510809-28-00 Metastatic Castration-sensitive Prostate Cancer 5 2021-09-27
POLAR BEAR Ended

2022-502887-19-00 Diffuse Large B-Cell Lymphoma 5 2020-08-18
A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolis… Ended

2023-503794-38-00 Prevention of stroke or systemic embolism in atrial fib 5 2022-11-24